Cantargia and Glycotope Biotechnology signs production agreement for lead product candidate CAN04

Lund, Sweden and Heidelberg, Germany – July 3, 2015 – Cantargia AB and Glycotope
Biotechnology GmbH today announced an agreement on the production of Cantargia’s
proprietary monoclonal antibody CAN04. The product candidate CAN04 is directed
against the target molecule IL1RAP, expressed on cancer stem cells as well on
mature cancer cells. Through the agreement, Glycotope Biotechnology will be
Cantargia’s production partner to obtain material for the clinical studies of
CAN04 in cancer patients.
Glycotope Biotechnology will be responsible for the development and GMP (Good
Manufacturing Practices) production of CAN04. Glycotope Biotechnology will
manufacture product to be used in both future toxicology studies and clinical
trials.

“The collaboration with Glycotope Biotechnology will be a cornerstone in the
development of CAN04. We look forward to work with Glycotope Biotechnology”,
says Göran Forsberg, CEO of Cantargia.

”To bring Cantargia´s lead drug candidate into clinical trials will be a great
opportunity for Glycotope Biotechnology as Contract Manufacturer for innovative
biopharmaceuticals”, says Franzpeter Bracht, COO of Glycotope Biotechnology.

About Cantargia
Cantargia AB (reg.no. 556791-6019) is a biotech company that is developing an
antibody-based cancer treatment, which attacks cancer stem cells as well as
mature cancer cells. The original discovery by the research team behind
Cantargia was the overexpression of a specific target molecule, IL1RAP, in
cancer stem cells in patients with leukaemia that is not found in normal stem
cells in the bone marrow. In preclinical studies (in vitro and in vivo) the
antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of
action, which are complementary. The company has selected a product candidate
for future studies in humans. Preclinical trials with Cantargia’s antibodies
have shown a potent antileukaemic effect. Parallel studies have shown an even
higher expression of IL1RAP in certain solid tumours. In 2015 Cantargia will be
carrying out the studies required for authorisation of clinical trials.

Sedermera Fondkommission is Cantargias Certified Adviser.

About Glycotope Biotechnology
Glycotope Biotechnology GmbH is an experienced service provider for the
development and GMP-production of active biopharmaceutical ingredients, as well
as fill and finish and all related services. Currently Glycotope Biotechnology
runs projects from supply for early up to late clinical trials and for market
production of an in vitro diagnostic. The integrated services cover the supply
of clinical trials up to product launch and market supply. Glycotope
Biotechnology supports its clients from process development & transfer, scale
-up, GMP-production including quality, bioassays and regulatory affairs. The
facilities in Heidelberg are designed for a product range comprising of
glycoproteins, antibodies and fusion proteins in several manufacturing lines up
to 1,000 L bioreactors for fed batch and continuous (perfusion) bioprocesses.

For further information, please contact:

Cantargia AB                          Glycotope Biotechnology GmbH
Dr. Göran Forsberg, CEO               Dr. Franzpeter Bracht, COO
Phone: +46 (0)46 275 62 60            Phone: +49 (0)30 94 89-2600
E-mail: goran.forsberg@cantargia.com  E-mail: franzpeter.bracht@glycotope.com
Website: www.cantargia.com            Website: www.glycotope.com